CoChat

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study

Open access
Odawara, M., Miyagawa, J., Iwamoto, N., Takita, Y., Imaoka, T., Takamura, T. · 2016 · Diabetes, Obesity and Metabolism
Cited by 56

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: To examine the efficacy and safety of once‐weekly dulaglutide 0.75 mg monotherapy compared with once‐daily liraglutide 0.9 mg in J apanese patients with type 2 diabetes ( T2D ) for 52 weeks. Methods: We conducted a phase III , randomized, 52‐week (26‐week primary endpoint), active‐ and placebo‐controlled trial comparing 492 J apanese patients (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70). Participants and investigators were blinded to treatment assignment for dulaglutide and placebo but not for liraglutide (open‐label comparator); after 26 weeks, patients randomized to placebo were switched to once‐weekly dulaglutide 0.75 mg (open‐label). The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks. Results: At week 52, dulaglutide decreased HbA1c significantly from baseline compared with liraglutide [least squares mean difference: −0.20; 95% confidence interval ( CI ) −0.39, −0.01; p = 0.04]. At week 52 (last observation carried forward), dulaglutide significantly decreased pre‐ and post‐dinner blood glucose ( BG ) levels, the mean of seven‐point self‐monitored BG profiles, the mean of all postprandial BG levels and circadian variation compared with liraglutide. Body weight was generally stable in both groups through 52 weeks. The most frequently reported adverse events were nasopharyngitis, constipation, nausea and diarrhoea. Eight dulaglutide‐treated (2.9%) and four liraglutide‐treated (2.9%) patients reported hypoglycaemia, with no event being severe. Conclusions: Monotherapy with once‐weekly dulaglutide 0.75 mg was effective and safe in J apanese patients with T2D , with better glycaemic control compared with once‐daily liraglutide 0.9 mg.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12602

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 11

  1. 10.1007/s12325-014-0166-0 · DOI
  2. 10.3810/pgm.2011.09.2479 · DOI
  3. 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
  4. 10.2337/dc13-2759 · DOI · Paper page
  5. 10.1111/dom.12534 · DOI
  6. 10.1111/dom.12540 · DOI
  7. 10.1185/03007991003672551 · DOI
  8. 10.1507/endocrj.EJ15-0401 · DOI
  9. 10.2337/dc11-1107 · DOI · Paper page
  10. 10.1161/HYPERTENSIONAHA.114.03062 · DOI
  11. 10.1111/j.1463-1326.2009.01194.x · DOI

Cited by

Metadata

Authors
Odawara, M., Miyagawa, J., Iwamoto, N., Takita, Y., Imaoka, T., & Takamura, T.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-01-08
Volume
18
Issue
3
Pages
249-257
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1951367122
Cited by
56
References
10
FWCI
4.56
Type
journal article
Language
en
Open access
hybrid
Funders
  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Boehringer Ingelheim

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.